Shares in Intersect ENT (NSDQ:XENT) rose slightly today after the steroid-eluting implant maker beat sales expectations on Wall Street with its third quarter results.
The Menlo Park, Calif.-based company posted a net loss of -$4.3 million on sales of $22.3 million for the 3 months ended Sept. 30, for sales growth of 21% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT beats Q3 sales estimates, raises full-year forecast appeared first on MassDevice.